ClinicalTrials.gg
Active, not recruitingNCT05243329Updated Jun 29, 2023

Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder

A Phase 2 interventional study of Psilocybin in Treatment Resistant Disorders and Post Traumatic Stress Disorder, sponsored by Halucenex Life Sciences Inc.. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-06-29.

Sponsored by Halucenex Life Sciences Inc. · Phase 2, Interventional, and Health services research

From the registry’s dates

  • Primary completion was expected by Oct 2023, 3 years ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing psilocybin in Stress Disorders, Post-Traumatic — 13 open to participants now, 16 under way, 3 of them phase 3. Psilocybin · Stress Disorders, Post-Traumatic.

Planned enrollment
14th of 20
20 · median 33
Started
2022
with 2 others
Phase 2
10 of 20
5 open now
Primary completion
2023-10
later than 0 of 15 live
Registered
3rd of 20
by date
Lead sponsor
1 of 20
Halucenex Life Sciences Inc.

Among the 20 studies testing psilocybin in Stress Disorders, Post-Traumatic, this one is the 14th largest by planned enrollment, is one of 3 that started in 2022, is one of 10 in phase 2, reaches primary completion later than 0 of the 15 other live ones, and was the 3rd registered.

Stress Disorders, Post-Traumatic

2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

13 of the 20 studies testing psilocybin in Stress Disorders, Post-Traumatic are open now, in 5 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About psilocybin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing psilocybin in Stress Disorders, Post-Traumatic, or all of them as a file.
02

Study summary

Post-traumatic stress disorder (PTSD) is a complex disorder expressed as a variety of neurobiological symptoms, including anxiety, re-experiencing, hyperarousal, and avoidance symptoms, along with comorbidities such as anxiety, depression, and increased risk for self-medicating substance abuse. Currently, there are only two approved medications in the United States (US) for PTSD, paroxetine and sertraline.

Psychedelic medications, including psilocybin, have recently received breakthrough designation by the US Food and Drug Administration (FDA) for other psychiatric indications. Although no formal clinical trials have yet investigated psychedelic substances for the treatment of PTSD, the available evidence warrants such an investigation. The present study aims to investigate the effect of psilocybin on treatment-resistant PTSD.

Read the detailed description

Post-traumatic stress disorder (PTSD) is a complex disorder expressed as a variety of neurobiological symptoms, including anxiety, re-experiencing, hyperarousal, and avoidance symptoms, along with comorbidities such as anxiety, depression, and increased risk for self-medicating substance abuse. Currently, there are only two approved medications in the United States (US) for PTSD, paroxetine and sertraline. These selective serotonin reuptake inhibitors (SSRIs) have limited efficacy. Furthermore, there is a lack of efficacious pharmacotherapy for treatment-resistant PTSD; PTSD remains a chronic and sometimes debilitating condition. New research into other treatment options for PTSD are warranted.

Psychedelic medications, including psilocybin, have recently received breakthrough designation by the US Food and Drug Administration (FDA) for other psychiatric indications. Psilocybin has received breakthrough designation for treatment of depression. Research on psilocybin has shown that it facilitates fear extinction in mice and promotes neuroplasticity, increasing neurogenesis, spinogenesis and synaptogenesis. These properties may contribute to antidepressive and anxiolytic effects. Psilocybin also reduces activity in the amygdala during threat responses; decreased amygdala reactivity is correlated with positive mood. This is particularly relevant since individuals with PTSD showed increased reactivity in the amygdala, which may increase the ability to process traumatic memories. Although no formal clinical trials have yet investigated psychedelic substances for the treatment of PTSD, the available evidence warrants such an investigation. The present study aims to investigate the effect of psilocybin on treatment-resistant PTSD.

03

Conditions studied

  • Treatment Resistant Disorders
  • Post Traumatic Stress Disorder
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • After signing and dating the documents, subject eligibility will be assessed. Subjects must meet the following criteria to be eligible for enrollment into the study.
  1. Subjects must be ≥18 and ≤70 years of age.
  2. Subjects must meet the Diagnostic \& Statistical Manual of Mental Disorders - Version V () criteria for TR-PTSD.
  3. Subjects must have treatment-resistant PTSD symptoms, defined as a CAPS score of ≥30 (signifying moderate to severe symptoms) following at least 3 months of prior SSRI or serotonin-norepinephrine reuptake inhibitor (SNRI) treatment in addition to at least 4 months of psychotherapy (adapted from Mithoefer et al, 2011).
  4. Subjects must be able to communicate in English.

Exclusion criteria

Exclusion Criteria:

  • Subjects meeting any of the following criteria will not be eligible for participation in the study:

    1. Pregnant individuals and those of childbearing age not using effective (e.g., oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine coil, intrauterine device, tubal ligation, or barrier method).
    2. Uncontrolled hypertension or BP ≥140/90 mmHg over 2 days, with at least 4 BP assessments completed.
    3. In the clinical judgement of the investigator, any hazard-posing medical, emotional, or significant character disorder or condition rendering unsuitability for the study. For example, poorly controlled diabetes, severe cardiovascular disease, seizure disorders, sleep apnea disorders (suspected or ineffectively treated), untrustworthiness, suicidality, etc.
    4. Any use of methamphetamines or any injection drug abuse in the past 30 days and/or a positive test for drugs of abuse (e.g., cocaine, amphetamines, opiates, benzodiazepines, etc.).
    5. Any other significant substance use disorder that may interfere with study objectives including consuming >5 cups of caffeinated coffee a day or inability, without discomfort, to refrain from smoking cigarettes or cannabis, or consuming alcohol for 7 hours.
    6. Blood draw or needle phobia.
    7. Suicidal attempt or active ideation deemed to present risk of suicide as judged by study clinical staff in past 30 days..
    8. \<14 or >42 or the Qualified investigator deems the patient sufficiently healthy to participate.
    9. Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder or brief psychotic disorder; current or previous history of bipolar disorder, or obsessive-compulsive disorder.
    10. Any uncontrolled eating disorder (e.g., purging or anorexia or worsening of directionally undesirable weight change of 5 kg in past 30 days).
    11. Subjects with a diagnosis of personality disorder which has a major impact on the subject's current psychiatric status
    12. Use of any drug, hallucinogen, or ketamine/esketamine within the past 30 days, or plan to use during the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Psilocybin treatment for treatment-resistant PTSD

    Experimental Treatment: Experimental: Psilocybin 10mg (low dose) on Day 7 25mg (high dose) on Day 14 10mg dose (optional top-up low dose) at Month 7 Treatment Description: Drug: Psilocybin drug product suspension Psilocybin is manufactured as a bulk API powder. The psilocybin drug product suspension is prepared by a compounding pharmacist at the clinic site. The psilocybin drug product suspension will be mixed in a glass with water to produce the psilocybin solution for oral consumption. Subjects will be instructed to orally consume the study medication in the glass in its entirety. Psilocybin will be administered in the following doses and at the following time points for this study: * 1 mL of 10mg/mL (low dose) on Day 7 (10 mg) * 2.5 mL of 10 mg/mL (high dose) on Day 14 (25 mg) * \[Optional dose\] 1 mL of 10mg/mL (low dose) on Month 7/Day 210 (10 mg)

    Drug: Psilocybin

Interventions

  • 10 mg or 25 mg oral aqueous psilocybin solution

06

What researchers measure

Primary outcomes

  1. Primary efficacy of psilocybin using the 11-Dimension Altered States of Consciousness (11D-ASC) will assess

    This is a 42 item questionnaire assessing patient-rated subjective intensity of psilocybin's effects

    Time frame: Day 14

  2. PTSD symptom severity as measured by the Clinician-Administered PTSD Scale (CAPS-5)

    Total CAPS-5 Scores range from 0-80. Higher scores indicate greater symptom severity.

    Time frame: Screening to 12 months follow up

  3. PTSD symptom severity as measured by the Posttraumatic Checklist for the DSM-5 (PCL-5)

    Total PCL-5 Scores range from 0-80. Higher scores indicate greater symptom severity.

    Time frame: Screening to 12 months follow up

  4. Subjective distress caused by traumatic events as measured by the Impact of Events Scale Revised (IES-R).

    The IES-R is a 22-item self-report measure where respondents are asked to identify a specific stressful life event and then indicate how much they were distressed or bothered during the past seven days by each "difficulty" listed. Items are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely"). The IES-R yields a total score (ranging from 0 to 88).

    Time frame: Screening to 12 months follow up

  5. Symptoms of Psychopathology as measured by the Symptom Checklist 90-R (SC90-R).

    The 90 items in the SC90-R are assessed by the subject using a 5-point rating scale.

    Time frame: Screening to 12 months follow up

  6. Symptom severity, treatment response, and the efficacy of treatment studies of patients with mental disorders as measured by the Clinical Global Impression - Improvement (CGI-I)/ Clinical Global Impression - Severity (CGI-S).

    The CGI-S scale is a 7-point, clinician-rated scale (ranging from 1 to 7, with 1 indicating a "normal state" and 7 indicating "among the most extremely ill patients").

    Time frame: Day 22

Secondary outcomes

  1. Anxiety as measured by the Beck Anxiety Inventory (BAI).

    The BAI is a 21-item self-report inventor. Total BAI Scores range from 0-63; higher scores indicate more severe anxiety.

    Time frame: Up to 12 month follow up

  2. Anxiety as measured by the State Trait Anxiety Inventory - Trait Version (STAI-T).

    The STAI-T scale consists of 20 items on a 4-point scale; Higher scores indicate greater anxiety.

    Time frame: Up to 6 month follow up

  3. Depression as measured by the Beck Depression Inventory (BDI).

    The BDI is a 21-item, self-report rating inventory with each item scored on a scale value of 0 to 3; higher total scores indicating more severe depression symptoms.

    Time frame: Up to 12 month follow up

  4. Depression as measured by the Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR).

    The QIDS-SR contains 16 items, with each item scored from 0 to 3.

    Time frame: Up to 12 month follow up

  5. Impairments in daily living as measured by the Sheehan Disability Scale (SDS).

    This is a 3-item, clinician administered questionnaire with all items rated on an 11-point continuum, with higher scores indicating more severe impairment. (0 meaning "no impairment" to 10 meaning "most severe").

    Time frame: Up to 12 month follow up

  6. Body Mass Index (BMI)

    Measure of body mass based on height and weight

    Time frame: Up to 12 month follow up

  7. Trauma Related Nightmare Survey

    trauma-focused survey to track sleep and nightmare-related information

    Time frame: Up to 12 month follow up

07

Study locations

1 site
  • Halucenex Life Sciences Inc.
    Windsor, Nova Scotia B0N2T0, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Oct 2023, 12 months after the start.

Of 31 industry-sponsored phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's planned 12 months is below that.

Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2021
First posted
Feb 17, 2022
StartActual
Oct 3, 2022
Primary completionEst.
Oct 30, 2023
CompletionEst.
Dec 30, 2023
Last update
Jun 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05243329
Lead sponsor
Halucenex Life Sciences Inc.
Collaborators
KGK Science Inc.
Responsible party
Sponsor
First posted
Feb 17, 2022
Start date
Oct 3, 2022
Primary completion
Oct 30, 2023 (estimated)
Completion
Dec 30, 2023 (estimated)
Last update
Jun 29, 2023

Study contacts

Lisa Batten, PhD
study director · Halucenex Life Sciences
Paige Stevens, MD
principal investigator · Contracted

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion